Volume 5, Issue 1 (2019)
Pharm Biomed Res 2019, 5(1): 1-5 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ghaffari J, Ghaffari N. Omalizumab for treatment of chronic urticaria: A review of effective dose. Pharm Biomed Res 2019; 5 (1) :1-5
URL: http://pbr.mazums.ac.ir/article-1-218-en.html
URL: http://pbr.mazums.ac.ir/article-1-218-en.html
1- Pediatric Infectious Diseases Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
2- Medical student, Mazandaran University of Medical Sciences, Sari, Iran
2- Medical student, Mazandaran University of Medical Sciences, Sari, Iran
Abstract: (2203 Views)
Omalizumab or Xolair®, a humanized anti-IgE monoclonal antibody, is effective and well-tolerated in patients with chronic spontaneous urticaria refractory to H1 antihistamines. The web search of several databases, including PubMed, EMBASE, Scopus, Google, SID, Magiran, and Irandoc, led to the selection of 60 articles. The search process was performed using the keywords of Xolair, omalizumab, urticaria, chronic urticaria, effect, and treatment. All studies have been conducted on people over 12 years of age with the exception of 2 articles investigating patients over 7 years old. Most studies have been performed on patients within the age range of 12-75 years and the maximum age of 81 years. Omalizumab has been administered at different doses for patients with chronic urticaria (75-600 mg). It has been shown to have a positive effect at all administered doses; however, it has the greatest effect when administered at the dose of 300 mg. The interval of subcutaneous injections was 2-6 weeks. In conclusion, the administration of this drug is effective at doses of 150 and 300 mg although the most effective dose is 300 mg.
Type of Study: Review article |
Subject:
Clinical Pharmacy
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-By-NC), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Contact Information
